Impact of exacerbations and admissions in chronic obstructive pulmonary disease;Impacto de las agudizaciones e ingresos en la EPOC

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL. 8, 2010, Pages 8-14

  Arnedillo Muñoz, Aurelio ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

COPD exacerbations; Economic burden; Hospitalizations; Mortality; Pulmonary function; Quality of life

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MORTALITY; QUALITY OF LIFE; SOCIAL ASPECT; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE PROGRESSION; EMERGENCIES; EUROPE; FORCED EXPIRATORY VOLUME; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MIDDLE AGED; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; UNITED STATES;

EID: 79951691434     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70061-2     Document Type: Article

References (59)

1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated December 2009. Disponible en: http://www.goldcopd.org/.
2. Rodríguez-Roisin R. Toward a consensus definition for COPD exacerbation. Chest 2000, 117:398s-401s.
3. Pauwels R., Calverley P., Buist A.S., Rennard S., Fucuchi Y., Stahl E., et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004, 98:99-107.
4. Hurst J.R., Wedzicha J.A. What is (and what is not) a COPD exacerbation: thoughs from the new GOLD guidelines. Thorax 2007, 62:198-199.
5. Almagro P., Calbo E., Ochoa de Echaguen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448.
6. Gunen H., Hacievliyagil S.S., Kosar F., Mutlu L.C., Gulbas G., Pehlivan E., et al. Factors affecting survival of hospitalized patients with COPD. Eur Respir J 2005, 26:234-241.
7. Garcia-Aymerich J., Monso E., Marrades R.M., Escarrabill J., Félez M.A., Sunyer J., et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation: EFRAM Study. Am J Respir Crit Care Med 2001, 164:1002-1007.
8. Langsetmo L., Platt R.W., Ernst P., Bourbeau J. Underreporting Exacerbation of Chronic Obstructive Pulmonary Disease in a Longitudinal Cohort. Am J Respir Crit Care Med 2008, 177:396-401.
9. Guía de práctica clínica de diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica. SEPAR-ALAT. Updated 2009. Disponible en: http://www.separ.es/.
10. Cote C.G., Dordelly L.J., Celli B.R. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007, 131:696-704.
11. Anzueto A., Leimer I., Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD 2009, 4:245-251.
12. Kirsten D.K., Taube C., Lehnigk B., Jörres R.A., Magnussen H. Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med 1998, 92:1191-1198.
13. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
14. Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999, 116:40-46.
15. Jones P.W., Wijkstra P.J. Quality of life in patients with chronic obstructive pulmonary disease. Eur Respir Mon 2006, 38:375-386.
16. Aaron S.D., Vandemheen K.L., Clinch J.J., Ahuja J., Brison R.J., Dickinson G., et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002, 121:688-696.
17. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
18. Miravitlles M., Ferrer M., Pont A., Zalacain R., Alvarez-Sala J.L., Masa F., et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004, 59:387-395. IMPAC Study Group.
19. Spencer S., Jones P.W. Time course of recovery of health status following an nfective exacerbation of chronic bronchitis. Thorax 2003, 58:589-593.
20. Esteban C., Quintana J.M., Moraza J., Aburto M., Egurrola M., España P.P., et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med 2009, 103:1201-1208.
21. Fan S.F., Curtis J.R., Tu S.P., McDonell M.B., Fihn S.D. Using quality of life to predict hospitalizations and mortality in patients with chronic obstructive pulmonary disease. Chest 2002, 122:429-436.
22. Spencer S., Calverley P.M., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702.
23. Miravitlles M., Soriano J.B., Garcia-Rio F., Muñoz L., Duran-Tauleria E., Sanchez G., et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868.
24. Halpin D., Miravitlles M. Chronic Obstructive Pulmonary Disease. The disease and its burden to society. Proc Am Thorac Soc 2006, 3:619-623.
25. Ruchlin H.S., Dasbach E.J. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001, 19:623-642.
26. Hilleman D.E., Dewan N., Malesker M., Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000, 118:1278-1285.
27. Regueiro C.R., Hamel M.B., Davis R.B., Desbiens N., ConnorsAF J.r., Phillips R.S. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment). Am J Med 1998, 105:366-372.
28. National Heart, Lung, and Blood Institute. Chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung, and Blood Institute; 2004. Disponible en: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf.
29. Chronic obstructive pulmonary disease. European Lung White Book 2003, European Respiratory Society and European Lung Foundation, European Respiratory Society, Lausanne, p. 34-43.
30. Wouters E.F. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003, 97:S3-14.
31. Britton M. The burden of COPDin the UK: results from the Confronting COPD survey. Respir Med 2003, 97:S71-S79.
32. Pauwels R.A., Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364:613-620.
33. Miravitlles M., Murio C., Guerrero T., Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003, 123:784-791.
34. Masa J.F., Sobradillo V., Villasante C., Jiménez-Ruíz C., Fernández-Fau L., Viejo J.L., et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol 2004, 40:72-79.
35. Vestbo J. Socioeconomic burden of chronic obstructive pulmonary disease. Eur Respir Mon 2006, 38:463-469.
36. Andersson F., Borg S., Jansson S.A., Jonsson A.C., Ericsson A., Prütz C., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002, 96:700-708.
37. Oostenbrink J.B., Rutten-van Mölken M.P. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004, 98:883-891.
38. Au D.H., Udris E.M., Fihn S.D., McDonell M.B., Curtis J.R. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med 2006, 166:326-331.
39. Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:1-10.
40. Connors A.F., Dawson N.V., Thomas C., Harrell F.E., Desbiens N., Fulkerson W.J., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996, 154:959-967.
41. Ranieri P., Bianchetti A., Margiotta A., Virgillo A., Clini E.M., Trabucchi M. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc 2008, 56:909-913.
42. Groenewegen K.H., Schols A.M.W.J., Wouters E. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003, 124:459-467.
43. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
44. Seemungal T.A., Hurst J.R., Wedzicha J.A. Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009, 4:203-223.
45. Fuso L., Incalzi R.A., Pistelli R., Muzzolon R., Valente S., Pagliari G., et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995, 98:272-277.
46. Solanes I., Casan P., Sangenís M., Calaf N., Giraldo B., Güell R. Factores de riesgo de mortalidad en la EPOC. Arch Bronconeumol 2007, 43:445-449.
47. Nevins M.L., Epstein S.K. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest 2001, 119:1840-1849.
48. Patil S.P., Krishnan J.A., Lechtzin N., Diette G.B. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003, 163:1180-1186.
49. Rieves R.D., Bass D., Carter R.R., Griffith J.E., Norman J.R. Severe COPD and acute respiratory failure. Correlates for survival at the time of tracheal intubation. Chest 1993, 104:854-860.
50. Gunen H., Hacievliyagil S.S., Kosar F., Mutlu L.C., Gulbas G., Pehlivan E., et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005, 26:234-241.
51. Pinckney R.G., O'Brien R., Piccirillo J.F., Littenberg B. Evaluation of co-morbidity indices in patients admittedfor chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 2004, 61:209-212.
52. Yang S., Tan K.L., Devanand A., Fook-Chong S., Eng P. Acute exacerbation of COPD requiring admission to the intensive care unit. Respirology 2004, 9:543-549.
53. Seneff M.G., Wagner D.P., Wagner R.P., Zimmerman J.E., Knaus W.A. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995, 274:1852-1857.
54. Tan W.C. Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease. COPD 2004, 1:225-247.
55. Roche N., Zureik M., Soussan D., Neukirch F., Perrotin D. Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. Eur Respir J 2008, 32:953-961. Urgence BPCO (COPD Emergency) Scientific Committee.
56. Sanjaume M., Almagro P., Rodríguez-Carballeira M., Barreiro B., Heredia J.L., Garau J. Mortalidad posthospitalaria en pacientes reingresadores por EPOC. Utilidad del índice BODE. Rev Clin Esp 2009, 209:364-370.
57. Calverley P.M.A., Anderson J.A., Celli B.R., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007, 356:775-789.
58. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. UPLIFT Study Investigators.
59. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of Budesonida/Formoterol added to Tiotropium in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2009, 180:741-750.